张婷婷等

    [摘要] 目的 探讨血管紧张素转换酶-插入/缺失(ACE-I/D)多态性对厄贝沙坦临床降压效果的影响。 方法 计算机检索PubMed、EMBase、中国期刊全文数据库(CNKI)、万方数据库、维普(VIP)、中国医院知识资源总库(CHKD)等中英文数据库，选取厄贝沙坦单药治疗组的原发性高血压患者为研究对象、各基因型治疗前后血压改变值作为结局指标，采用RevMan 5.2对符合纳入排除标准的研究进行Meta分析。 结果 共纳入4个研究，408例原发性高血压患者，在降低舒张压疗效方面ACE-ID基因型优于DD基因型，其多态性与厄贝沙坦显著降低舒张压有关[SMD = 1.91，95%CI(0.31，3.50)，P 0.05)。 结论 在使用厄贝沙坦的原发性高血压患者中，ID基因型患者舒张压的降低幅度优于DD基因型患者。该结论还需长期、大样本、高质量的研究进一步验证。

    [关键词] 厄贝沙坦；基因多态性；血管紧张素转化酶；Meta分析

    [中图分类号] R544.1 [文献标识码] A [文章编号] 1673-7210(2015)02(b)-0110-05

    [Abstract] Objective To investigate the effect of angiotensin converting enzyme-insertion/deletion (ACE-I/D) gene polymorphisms on clinical efficacy of Irbesartan systematically. Methods The literatures were searched from the electronic databases： PubMed， EMBase， CNKI， Wanfang， VIP， CHKD and so on. Patients with essential hypertension with Irbesartan monotherapy were selected as the objects of the study. The change value of blood pressure (BP) at predose and postdose of genotypes was selected as outcome indicator. Meta-analysis was performed by RevMan 5.2 software according to inclusive criteria and exclusion criteria. Results A total of 4 studies were included ......